Ingenol Mebutate: A Succinct Review of a Succinct Therapy

Dermatology and Therapy

Volumn 4, Issue 2, 2014, Pages

  Alchin, David Rhys ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Actinic keratosis; Dermatology; Field therapy; Ingenol 3 angelate; Ingenol mebutate; Picato; Solar keratosis; Squamous cell carcinoma

Indexed keywords

DICLOFENAC; FLUOROURACIL; IMIQUIMOD; INGENOL MEBUTATE;

ACTINIC KERATOSIS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APPLICATION SITE ERYTHEMA; APPLICATION SITE IRRITATION; APPLICATION SITE PAIN; APPLICATION SITE PRURITUS; APPLICATION SITE SCABBING; APPLICATION SITE SCAR; CANCER PREVENTION; CELL DEATH; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; GEL; HUMAN; IMMUNOSTIMULATION; PIGMENT DISORDER; REVIEW; SKIN CRUSTING; SKIN FLAKING; SKIN MANIFESTATION; SKIN SCALING; SQUAMOUS CELL CARCINOMA; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84915820021     PISSN: 21938210     EISSN: 21909172     Source Type: Journal    
DOI: 10.1007/s13555-014-0061-2     Document Type: Review

References (20)

1. Berman B, Cockerell CJ. Pathobiology of actinic keratosis: ultraviolet-dependent keratinocyte proliferation. J Am Acad Dermatol. 2013;68(1 Suppl 1):S10–9.
2. Sotiriou E, Apalla Z, Vrani F, Lallas A, Chovarda E, Ioannides D. Photodynamic therapy vs. imiquimod 5% cream as skin cancer preventive strategies in patients with field changes: a randomized intra individual comparison study. JEADV. 2014.
3. Chia A, Lim A, Shumack S, Moreno G. Actinic keratoses. Aust Fam Phys. 2007;36(7):539.
4. Goldenberg G. Optimal treatment of actinic keratosis. Clin Interv Aging. 2014;9:15–6.
5. Perl M, Goldenberg G. Field therapy in the treatment of actinic keratosis. Cutis. 2014;93(4):172–3.
6. Dodds A, Chia A, Shumack S. Actinic keratosis: rationale and management. Dermatol Ther (Heidelb). 2014;4(1):11–31.
7. Lebwohl M, Shumack S, Stein Gold L, Melgaard A, Larsson T, Tyring SK. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol. 2013;149(6):666–70.
8. Siller G, Rosen R, Freeman M, Welburn P, Katsamas J, Ogbourne SM. PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial. Australas J Dermatol. 2010;51(2):99–105.
9. Gupta AK, Paquet M. Ingenol mebutate: a promising treatment for actinic keratoses and nonmelanoma skin cancers. J Cutan Med Surg. 2013;17(3):173–9.
10. Anderson L, Schmieder GJ, Werschler WP, Tschen EH, Ling MR, Stough DB, et al. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. J Am Acad Dermatol. 2009;60(6):934–43.
11. Rosen RH, Gupta AK, Tyring SK. Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response. J Am Acad Dermatol. 2012;66(3):486–93.
12. Samrao A, Cockerell CJ. Pharmacotherapeutic management of actinic keratosis: focus on newer topical agents. Am J Clin Dermatol. 2013;14(4):273–7.
13. Fidler B, Goldberg T. Ingenol mebutate gel (picato): a novel agent for the treatment of actinic keratoses. Pharm Ther. 2014;39(1):40–6.
14. Stahlhut M, Bertelsen M, Hoyer-Hansen M, Svendsen N, Eriksson AH, Lord JM, et al. Ingenol mebutate: induced cell death patterns in normal and cancer epithelial cells. JDD. 2012;11(10):1181–92.
15. Ersvaer E, Kittang AO, Hampson P, Sand K, Gjertsen BT, Lord JM, et al. The protein kinase C agonist PEP005 (ingenol 3-angelate) in the treatment of human cancer: a balance between efficacy and toxicity. Toxins. 2010;2(1):174–94.
16. Fallen RS, Gooderham M. Ingenol mebutate: an introduction. Skin Ther Lett. 2012;17(2):1–3.
17. Siller G, Gebauer K, Welburn P, Katsamas J, Ogbourne SM. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study. Australas J Dermatol. 2009;50(1):16–22.
18. Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate gel for actinic keratosis. New Engl J Med. 2012;366(11):1010–9.
19. Dosik JS, Damstra M, Udell C, Welburn P. Evaluation of the skin sensitization, photo irritation, and photoallergic potential of ingenol mebutate gel in healthy volunteers. J Clin Aesthet Dermatol. 2014;7(4):35–42.
20. Martin G, Swanson N. Clinical findings using ingenol mebutate gel to treat actinic keratoses. J Am Acad Dermatol. 2013;68(1 Suppl 1):S39–48.